A multi-target mRNA-LNP showed tolerability and disease-stabilization signals across several spontaneous canine cancers.
Evidence
Small veterinary treatment cohort of 8 dogs with adrenal, hepatic, perianal, vulvar, and pulmonary malignancies reported stable disease in 6/8, progression in 2/8, and grade 1 anorexia, chills, or fatigue in 2/8 at median 168 days follow-up.
Caveat
The uncontrolled eight-dog sample and stable-disease endpoint do not establish comparative efficacy or human oncology benefit.
Simplified
Immunosuppression within the (TME) profoundly inhibits anti-tumor immunity, presenting a formidable challenge in cancer therapeutics. Despite this recognized obstacle, multi-targeted immunomodulatory strategies remain elusive. Here we developed a novel mRNA-lipid nanoparticle (LNP) vaccine designed to reprogram key cellular mediators of immune suppression within the TME, including C-C motif chemokine ligand 22 (CCL22), transforming growth factor-β (TGF-β), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), Galectin-3, programmed cell death ligand 1 (PD-L1), indoleamine 2,3-dioxygenase 1 (IDO1), and arginase 1 (ARG1). This was evaluated in a cohort of canines with spontaneous neoplasms, encompassing adrenal, hepatic, perianal, vulvar, and pulmonary malignancies. The vaccine demonstrated good tolerability, with only mild adverse events (Grade 1 anorexia, chills, and fatigue) observed in 25% of subjects (2/8). Remarkably, 75% of treated animals (6/8) achieved stable disease, with the median progression-free interval not yet reached a median follow-up of 168 days post-treatment initiation. Two dogs experienced disease progression. The overall disease control rate was 75%. In addition, vaccine administration reversed hematological and biochemical abnormalities and alleviated paraneoplastic syndromes associated with these malignancies. These findings demonstrate that our mRNA-LNP vaccine effectively exerts anti-tumor effects across various cancer types, offering a promising strategy for enhancing anti-tumor immunity in both veterinary and human oncology.
Key numbers
75%
6 of 8 dogs achieved post-treatment.
25%
Adverse Events
2 of 8 dogs experienced mild side effects.
168 days
Follow-up period for treated dogs was 168 days.
Full Text
We can’t show the full text here under this license.
